This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future

Corporate Overview March 2019 NASDAQ:

GALT www.galectintherapeutics.com Harold H. Shlevin, Ph.D. Chief Executive Officer Jack W. Callicutt Chief Financial Officer Exhibit 99.1

This presentation contains, in addition

to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as "may,"

"estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the

statements. These statements include those regarding potential therapeutic benefits of our drugs, expectations, plans and timelines related to our clinical trials, supporting activities, potential partnering opportunities and estimated spending for

2019 and beyond. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, our trials and supporting CMC information may not lead to positive outcomes or

regulatory approval. We may experience delays in our trials, which could include enrollment delays. Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and

costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Strategies and spending projections may

change. We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to complete our clinical trials or further develop and/or fund any future studies or trials. To date, we have incurred operating

losses since our inception, and our future success may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year

ended December 31, 2018, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking

statements. Forward-Looking Statements

Galectin is advancing its lead

compound, GR-MD-02 (belapectin), towards a Phase 3 trial in NASH Cirrhosis, First Patient ~ Fall, 2019 NASH market opportunity estimated to reach $35 - $40 Billion/Year by 2025* Proven biological activity in both Phase 2b and animal trials Phase 3

ready asset - target starting Fall, 2019 First randomized clinical trial of any drug to demonstrate statistically significant positive efficacy in compensated NASH cirrhosis without varices (NASH-CX trial) Demonstrated efficacy in a population

with a high degree of clinical unmet need with no available therapies and few in development GR-MD-02 is protected by a strong and robust IP portfolio of 77 granted and 27 pending patents across a broad group of human diseases through at least 2033

Cover composition of matter for complex carbohydrate drugs and/or various methods of use in treatment of fibrosis and other relevant diseases. Experienced Leadership * Deutsche Bank "NASH - the next big global epidemic in 10

years?" July 14, 2014 Galectin Summary

Investigating NASH cirrhosis, a

condition that is more closely linked to liver failure and its life-threatening implications than earlier stages of NASH Have engaged leading NASH experts to provide advice and counsel to strengthen our plan for the NASH-RX Phase 3 clinical trial

Type C Meeting with the FDA on February 6, 2019 discussed Galectin's proposal for use of progression to varices as the primary surrogate endpoint moving forward FDA supports use of progression to varices as a potential surrogate endpoint and

progression to large varices as a component of a composite clinical benefit endpoint pending additional requested information NASH cirrhosis patients with portal hypertension are at risk of developing esophageal varices which may bleed and exhibit

other decompensating events. Protocol is now in the process of finalization to provide meaningful clinical outcomes and address suggestions made by FDA First Patient First Visit target Fall, 2019; Top Line Data: Q4 2022 Galectin Phase 3 Trial

Over 34 years of relevant experience

Solvay Pharmaceuticals, CEO CIBA Vision Ophthalmics (n/k/a Novartis Vision), SVP & co-founder Tikvah Therapeutics, Founder and CEO CIBA-Geigy Pharmaceuticals Harold H. Shlevin, Ph.D., CEO and President Over 27 years of relevant experience Reach

Health, CFO, Vystar Corporation, CFO, Corautus Genetics, Deloitte Jack W. Callicutt, CFO Over 34 years of relevant experience: Koor Biotechnologies, Charm Sciences, Glycogenesis, HU Medical School (Jerusalem), and Harvard University Eli Zomer,

PhD, Pharm Development Over 30 years experience in clinical development, medical affairs & regulatory processes. UCB Inc., Abbott Laboratories, Solvay Pharmaceuticals Adam Allgood, Pharm D., Clinical Development Rex Horton, Regulatory Over 29

years of experience; Director Regulatory Affairs at Solvay Pharmaceuticals and Chelsea Therapeutics; Georgia Institute of Technology Head of regulation, quality assurance and manufacturing Strong, experienced management team

Contents General NASH Competitive

Landscape NASH Cirrhosis and GR-MD-02 Phase 2b Results Phase 3 plans Cancer Immunotherapy Combination Summary

Source: Torres DM, et al. Clin

Gastroenterol Hepatol. 2012;10:837-858. NASH Disease Progression

Industry Pipeline Is Relatively Less

Crowded in Cirrhotic NASH GR-MD-02 Uniquely Positioned

Contents General NASH Competitive

Landscape NASH Cirrhosis and GR-MD-02 Phase 2b Results Phase 3 plans Cancer Immunotherapy Combination Summary

Galectin is developing a compound

for the most serious stages of the disease Reprinted from: B Riley FBR Research, Feb., 2019

GR-MD-02 targets and disrupts the

function of galectin-3, which plays a major role in diseases that involve organ fibrosis Galectin proteins' ability to dimerize creates the opportunity for galectins to link glycoproteins and form a lattice structure on the cellular surface

and to promote cell-cell and cell-matrix interactions Galectin-3 expression is up-regulated in established human fibrotic liver disease, and disruption of Galectin-3 can markedly reduce liver fibrosis (*) * Source: Henderson et al., PNAS, 2006.

Central Role of Gal-3 in Multiple Pathological Processes

There is currently no treatment for

NASH cirrhosis, a progressive disease that can lead to significant mortality Fatty Liver NASH: Cell Death Inflammation Fibrosis 1 Garcia-Tsao, G., Friedman, S., Iredale, J., Prinzani, M. Hepatology. 2010;51:14451449 Compensated Cirrhosis

Decompensated Cirrhosis Stage 1 Stage 2 Stage 3 and 4 No Varices Varices Develop Bleeding, Ascites, Encephalopathy Low one year mortality (1-3%) ~50% one year mortality 6 >10 >12 Portal Pressure (mmHg) The majority of companies are

focused on pre-cirrhotic NASH Few companies with Phase 2/3 trials in NASH cirrhosis Unlike many companies in the NASH space, Galectin is focusing on the compensated cirrhotic patients

Unlike many companies in the NASH

space, Galectin is focusing on the compensated cirrhotic patients The majority of companies are focused on pre-cirrhotic NASH Few companies with Phase 2/3 trials in NASH cirrhosis Patients with NASH cirrhosis without varices are at high risk for

severe complications and have a high degree of unmet need Fatty Liver NASH: Cell Death Inflammation Fibrosis 1 Garcia-Tsao, G., Friedman, S., Iredale, J., Prinzani, M. Hepatology. 2010;51:14451449 Compensated Cirrhosis Decompensated Cirrhosis Stage

1 Stage 2 Stage 3 and 4 No Varices Varices Develop Bleeding, Ascites, Encephalopathy Low one year mortality (1-3%) ~50% one year mortality 6 >10 >12 Portal Pressure (mmHg) Significance of Targeting NASH Cirrhosis without Varices: Once

NASH progresses to cirrhosis, patients are at risk for severe complications, liver failure, and death and the condition is not reversible with lifestyle changes alone Presence/absence of varices is part of standard care for NASH patients and is

easily assessed by endoscopy, and an important goal of treatment of patients with Stage 1 is to prevent progression to varices and complications The only currently available therapy for NASH cirrhosis is liver transplant when clinical progression is

4 Liver-related complications

(varices/bleeding, ascites, hepatic encephalopathy, liver-related death, or transplant) Endpoints Baseline Week 54 Primary Endpoint Portal Pressure: HVPG2 Secondary Endpoints Liver Biopsy3 Endoscopy (varices)

Complications4 1 Subjects were enrolled across 36 sites in the US 2 HVPG = Hepatic Venous Pressure Gradient 3 Histologic staging & quantitative morphometry for collagen Major Inclusion Criteria NASH cirrhosis (biopsy) HVPG2

6 mmHg No cirrhosis complications No or small varices (50:50) Every other week infusion x 26 Treatment #Patients Placebo 54 GR-MD-02 2 mg/kg 54 GR-MD-02 8 mg/kg 54 Additional trial data on website NASH-CX was a randomized, double-blind,

placebo-controlled phase 2b clinical trial that enrolled 162 NASH cirrhosis patients1 Dosing and Administration Phase 2b Trial Design

The GR-MD-02 2 mg/kg group showed a

statistically significant reduction in HVPG from baseline to week 54 for patients without varices Placebo GR-MD-02 2 mg/kg GR-MD-02 8 mg/kg 13 9 8 10 11 12 n=33 Baseline Week 54 n=31 Baseline n=25 Week 54 n=23 n=23 Baseline n=22 Week 54 HVPG (mmHg)

Statistically significant effect of 2 mg/kg dose on change in HVPG at baseline Mean Change from Baseline to Week 541 0.8 mmHg -1.08 mmHg p = 0.01 0.15 mmHg ns 1 ITT with LOCF, ANCOVA with LSD Mean SEM

43% of patients without varices in

the GR-MD-02 2mg/kg group showed a 2 mmHg and 20% decrease from baseline compared to 13% in the placebo group p = 0.011 Placebo GR-MD-02 2 mg/kg 50% 10% 0% 4/31 20% 30% 40% 10/23 13% 44% 1 Chi Square High bar to demonstrating efficacy

that is contingent on clinically important reduction in HVPG from baseline Percentage of Patients Who Had a Clinically Relevant Reduction in HVPG With: 2 mmHg Decrease From Baseline AND 20% Decrease From Baseline

Patients in the 2 mg/kg treatment

group showed statistically significant improvement of liver cell death on liver biopsy1 Placebo GR-MD-02 2 mg/kg GR-MD-02 8 mg/kg p = 0.03 p = 0.09 0.4 0.2 0.0 -0.2 n=54 n=54 Mean SEM n=53 Change in Hepatocyte Ballooning Score at Week 54 In

the total population there was improvement in cell death, a critical feature of NASH 1 ITT population Ordinal Logistic Regression Analysis

Significantly fewer new varices

developed in treatment groups versus placebo, and no patients in the 2 mg/kg treatment group developed new varices Trial hit a clinically relevant endpoint related to patient outcomes 1 Chi Square Percent New Varices Formation Placebo GR-MD-02 2

mg/kg 6/33 0/25 p = 0.02 20 15 10 5 0

GR-MD-02 has demonstrated efficacy

in two clinically meaningful endpoints, where no current therapies exist Portal hypertension (PH) is a critical, clinically important consequence of cirrhosis and responsible for the majority of associated complications Portal pressures of 10

mmHg are associated with increased risk of decompensation, varices, hepatocellular carcinoma, and 1-year mortality For example, an HVPG 10 mmHg is associated with a 28% rate of varices development and a 20% rate of first decompensation at two

years Patients with an HVPG <10 mmHg have only a 10% chance of developing clinical decompensation (over median follow-up of 4 years) For patients with compensated cirrhosis and PH without varices, there are no specific therapies indicated for

reducing PH and/ or directly treating the underlying liver disease Beta-blockers are efficacious in improving outcomes in patients with portal hypertension and varices, but likely do not prevent development of varices/ slow disease progression in

early stage cirrhosis patients As a result, clinical guidelines in the US and EU do not recommend the use of beta-blockers for the prevention of variceal formation Further, Compensated cirrhosis patients with no major complications carry a median

survival of >12 years, but compensated patients with varices have a worse prognosis (3-fold higher one year mortality rates) Gastroenterology, 2007;133:481-488 HVPG 10 mmHg Sources: AASLD Practice Guidelines, Garcia-Tsao et al.

HEPATOLOGY, VOL. 65, NO. 1, 2017; La Mura et al. World J Hepatol 2015 April 8; 7(4): 688-695 Baveno guidelines; Ripoll et al. GASTROENTEROLOGY 2007;133:481-488; Brunt, Semin Liver Dis., 2004; 24; UpToDate; Cordon, World J Gastrointest Endosc.,

Portal Hypertension is the Main

Driver of Decompensation

GR-MD-02 was safe and well-tolerated

No differences between treatment groups in the number of patients with treatment emergent adverse events (AEs), grade 3/4 AEs, serious adverse events (SAE), or grade 3/4 laboratory abnormalities All but 2 SAEs were unrelated to study drug; 2

patients in 8 mg/kg group had SAEs that were possibly related to study drug 1 There was one death due to complications of a surgical procedure that was unrelated to study drug 3 There was a low patient dropout rate of 6% which suggests the drug was

well tolerated and patients were adherent to the regimen (only one patient was removed from study for an AE possibly related to study drug 2 ) 1 Two SAEs were determined by the PI to be possibly related to study drug (transient ischemic attack and

worsening of hyponatremia, both GR8); All others SAEs were felt to be unrelated to study drug 2 Possibly related to drug: spasmodic cough (1); Unrelated to study drug: esophageal variceal bleeding (2), sepsis (1), pancreatitis (1) 3 Pulmonary

embolism following hernia repair surgery, judged to be unrelated to study drug

Positive effects of GR-MD-02 shown

in a subset of patients in the NASH-CX trial has allowed the company to reach its current Phase 3 development trajectory After incorporating advice and guidance from the FDA, Galectin announced on May 14, 2018 that the Company is proceeding with

plans for a Phase 3 clinical trial program for GR-MD-02 in NASH cirrhosis This plan is essentially complete and was discussed with FDA at a February 6 2019 meeting; additional input expected from CRO and others Target Patient Population Patients

with NASH cirrhosis without esophageal varices FDA indicated its support of the potential use of progression to varices as a surrogate endpoint and progression to large varices (or to small varices with a weal) as a component of a composite clinical

benefit endpoint (subject to additional information) is supportive of the potential use a composite clinical benefit Phase 3 Trial Design Further details of the Phase 2b trial results are available on our website

Summary of GR-MD-02 in NASH

Cirrhosis NASH-CX is the first clinical trial to show positive results in compensated NASH cirrhosis without esophageal varices Clinically meaningful effect in reducing portal pressure in a subgroup of patients Improvement in liver cell death, a key

component of NASH Reduction in the development of new esophageal varices Drug was safe and well-tolerated Following leadership meeting with FDA in May 2018, determined to be Phase 3-ready FDA in Feb 2019 meeting indicated its support for progression

to varices as a surrogate endpoint and progression to large varices (or to small varices with a weal) as a component of a composite clinical benefit endpoint The presence of varices is part of Standard of Care for patients and can easily be assessed

with endoscopy 50% of cirrhotic NASH patients do not have varices when diagnosed Further awareness of NASH will lead to early diagnosis which will increase the number of patients without varices These results have propelled the development program

to Phase 3 in consultation with Key Opinion Leaders (KOL) and FDA

Contents General NASH Competitive

Landscape NASH Cirrhosis and GR-MD-02 Phase 2b Results Phase 3 plans Cancer Immunotherapy Combination Summary

The focus and goal of the